High Levels of Protein, Mena, Linked to Taxol Resistance in Breast Cancer Patients

High Levels of Protein, Mena, Linked to Taxol Resistance in Breast Cancer Patients
Researchers have identified a biomarker that may help predict which breast cancer patients are likely to respond to microtubule-stabilizing drugs like Taxol (paclitaxel). The protein, called Mena, is involved in a newly discovered mechanism through which highly metastatic cancer cells become resistant to such drugs, and blocking it may be a promising approach to improve their response to Taxol. The study, "Mena confers resistance to Paclitaxel in triple-negative breast cancer," was published in Molecular Cancer Therapeutics. "Drugs that target that pathway restore paclitaxel sensitivity to cells expressing Mena," Frank Gertler, an MIT professor of biology and member of the Koch Institute for Integrative Cancer Research, said in a press release. "The study also suggests that during the course of treatment it might be worth monitoring the level of Mena. If the levels begin to increase, it might suggest that switching to another type of therapy could be useful." The Mena protein is known to interact with the cell's cytoskeleton to help the cells become mobile. Mena, and its isoform Mena invasive, or MenaINV, are highly expressed in various types of cancers, and are established drivers of metastasis. In a prior study, Gerter and his team found that high levels of these proteins in breast cancer patients were associated with increased metastasis and lower survival rates. Now, the researchers wondered whether Mena and MenaINV cou
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.